Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB-4746 in Amyotrophic Lateral Sclerosis
NCT07369076Phase 2Recruiting
- Sponsor
- Nura Bio
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of NB-4746 in amyotrophic lateral sclerosis (ALS), sponsored by Nura Bio. Started Mar 2026; status: recruiting.
02
Drugs
NB-4746
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07369076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369076.